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26ABSTRACT
Background. The waiting time for deceased-donor kidney-only transplantations in Japan
is long. Herein, we assessed the effect of length of dialysis on the outcomes of these
patients.
Methods. We divided patients into 2 groups based on length of dialysis (Group A, <15
years, and Group B, 15 years), and compared the background and outcomes after kidney
transplantation.
Results. Group A included 210 patients and Group B included 35 patients. In Group
B, 20% of transplants were from living donors. Patient age (P ¼ .017) and the hepatitis
C infection rate (P ¼ .018) were signiﬁcantly higher in Group B, whereas hypertension
(P ¼ .011), diabetes (P ¼ .041), and ABO-incompatibility rates (P ¼ .015) were
signiﬁcantly higher in Group A. The 5- and 10-year survival rates were 97.0% and
95.4%, respectively, in Group A and 97.1% and 97.1%, respectively, in Group B. The
5- and 10-year graft survival rates were 95.4% and 84.8%, respectively, in Group A
and 97.1% and 73.1%, respectively, in Group B. There were no signiﬁcant differences
between the groups in patient survival (P ¼ .74) and graft survival (P ¼ .72). The 5- and
10-year cardiovascular event-free survival rates were 95.9% and 92.4%, respectively, in
Group A and 88.6% and 76.8%, respectively, in Group B. Cardiovascular event-free
survival was signiﬁcantly higher in Group A (P ¼ .038). Cox stepwise multivariate analysis
indicated that length of dialysis was a signiﬁcant predictor of cardiovascular events (hazard
risk, 1.007; range, 1.001e1.012; P ¼ .012).
Conclusion. The prognosis after kidney transplantation is promising even after a long
length of dialysis, although evaluation of the cardiovascular risk is needed in these cases.*Address correspondence to Midori Hasegawa, Department of
Nephrology, Fujita Health University School of Medicine, 1-98
Dengakugakubo Kutukaek-cho, Toyoake, Aichi 470-1192,
Japan. E-mail: mhase@fujita-hu.ac.jpAREVISED organ transplantation law was introduced inJapan on July 17, 2010. Prior to its introduction, organ
transplantation from brain-dead donors was permitted only
when the potential donor had previously agreed to the
donation under such circumstances and when the potential
donor’s family assented to organ donation. At present, the
organs of deceased individuals whose intentions regarding
organ donation are unknown can be donated after consent
is obtained from the families; as a result, the number of
brain-dead organ donations has increased ﬁve-fold. Among
the increased number of brain-dead donated organs,
donated kidneys are reportedly preferentially provided to6
.org/10.1016/j.transproceed.2015.12.010patients undergoing pancreas-kidney transplantation.
Accordingly, the number of kidney-only donations has
decreased from 175 in 2009 to 101 in 2014 [1]. The mean
waiting time until kidney transplantation was 15.6 years in
2010 [2]. Based on data from the Japanese registry for renal
replacement therapy, the cumulative 10-year survival rateª 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1. Patient Characteristics
All Patients (n ¼ 245)
Group A Dialysis
Length <15 y (n ¼ 210)
Group B Dialysis
Length 15 y (n ¼ 35) P
Male (%) 65.7 66.3 62.3 .85
Age (y) 42.6  1.3 41.6  0.9 48.1  2.0 .0017
Diabetes (%) 14.3 16.2 2.9 .041
BMI (kg/m2) 20.1  3.1 20.0  3.1 20.0  2.9 .75
Systolic BP (mm Hg) 138.4  1.5 139.3  1.6 131.2  4.3 .046
Diastolic BP (mm Hg) 83.6  0.9 84.6  1.0 77.3  2.7 .0062
Smoking (%) 34.3 35.7 25.7 .34
Previous CVD (%) 5.7 5.7 5.7 1.00
LVH 34.7 34.7 34.2 .96
Hypertension (%) 55.4 56.9 34.2 .011
HCV (%) 4.9 3.3 14.3 .018
Donor organ (%)
Deceased kidney, heartbeat 1.6 0.48 8.6 <.0005
Deceased kidney, no heartbeat 46.5 41.0 80.0 <.0005
Living, related 26.9 34.0 2.9 <.0005
Living, unrelated 25.0 24.6 8.6 <.0005
Underlying disease (%)
CGN 54.1 53.8 42.9 .82
Diabetic nephropathy 10.7 12.4 0 .03
Reﬂux nephropathy 3.7 3.8 2.9 .80
Nephrosclerosis 2.0 1.9 2.9 .69
ADPKD 1.6 1.4 2.9 .52
Other or unknown 27.9 26.7 48.5 .30
ABO-incompatible (%) 12.7 14.8 0 .015
HLA mismatch (A, B, DR)
0 11.1 11.4 8.8 .44
1 17.6 19.0 8.8 .15
2 31.1 31.0 32.4 .87
3 21.7 21.0 26.5 .47
4 8.6 7.6 14.7 .17
5 7.0 7.1 5.9 .79
6 2.9 2.9 2.9 .98
Immunosuppression (%)
Cyclosporine 51.7 53.2 42.4 .25
Tacrolimus 48.3 46.8 57.6 .25
Azathioprine 19.2 18.3 24.2 .42
MMF 18.3 19.2 12.1 .33
Mizoribine 39.2 39.4 36.4 .74
Everolimus 0.8 1.0 0 .57
Note: Data are presented as means  standard deviation, unless otherwise noted.
Abbreviations: BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; LVH, left ventricular hypertrophy; HCV, hepatitis C virus; CGN, chronic
glomerulonephritis; ADPKD, autosomal dominant polycystic kidney disease; HLA, human leukocyte antigen; MMF, mycophenolate mofetil.
KIDNEY TRANSPLANTATION IN JAPAN 27was 36.0%, 15-year survival rate was 22.8%, and 20-year
survival rate was 15.8% after dialysis for patients who
began dialysis after 1983 [3]. In the present study, we aimed
to assess the characteristics and outcomes of kidney trans-
plantation in patients at our institute after a long or short
period of dialysis.
PATIENTS AND METHODS
We retrospectively reviewed the clinical data from patients who
underwent kidney transplantation in our hospital from October
1990 to March 2014. Of 263 patients, 18 patients for whom sufﬁ-
cient data were unavailable were excluded. The remaining 245
kidney transplantations represented 3 from donors with a heartbeat,
115 from donors without a heartbeat, and 127 from living donors.
The data included recipient age, gender, cause of end-stage renaldisease, smoking history, left ventricular hypertrophy, blood pres-
sure, history of cardiovascular disease, and hepatitis C virus infec-
tion. Allograft survival, recipient survival, and cardiovascular events
were also reviewed. Because the mean waiting time before kidney
transplantation in Japan was 15.6 years, we divided the patients into
2 groups based on their length of dialysis before kidney trans-
plantation: Group A (length of dialysis <15 years) and Group B
(length of dialysis 15 years). None of the patients were lost to
follow-up, and the information on the prognosis was collected from
the scheduled hospital visits. Cardiovascular events were deﬁned as
cardiovascular death, acute coronary syndrome, hospitalization for
worsening heart failure, cerebral hemorrhage, and cerebral infarc-
tion. This study was conducted according to the Declaration of
Helsinki and the Japanese National Ethical Guidelines, and was
approved by the ethics committee of Fujita Health University
School of Medicine.
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Fig 1. Kaplan-Meier curves for patient survival. There was no sig-
niﬁcant difference between the groups in terms of patient survival.
The solid line represents Group A (dialysis <15 years), and the
dotted line represents Group B (dialysis 15 years).
28 TADA, HASEGAWA, SASAKI ET ALStatistical Analysis
Data analyses were performed using the Statistical Package for Social
Science (SPSS), Version 18.0 for Windows (SPSS Inc., Chicago, Ill,
United States). Variables are expressed as mean values  standard
deviation. The differences between groups were evaluated with the
Mann-Whitney U test for continuous variables and with the
chi-squared test for categorical variables. The differences in event-free
survival between the groups were examined using the Kaplan-Meier
method, and they were compared using the log-rank test. Hazard
ratios and 95% conﬁdence intervals were calculated for each factor
with Cox proportional hazards analysis. A multivariate model was
established by including all the variables with a P value of <.05 on
univariate analysis. The differences were considered statistically sig-
niﬁcant at P < .05.Gr
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Fig 2. Kaplan-Meier curves for graft survival. There was no sig-
niﬁcant difference between the groups in terms of graft survival.
The solid line represents Group A (dialysis <15 years), and the
dotted line represents Group B (dialysis 15 years).RESULTS
Table 1 shows patient characteristics. Group A comprised
210 patients and Group B comprised 35 patients. Group B
included 4 patients receiving kidneys from living donors and
31 patients receiving kidneys from deceased donors. Patient
age, rate of hepatitis C virus infection, and deceased
donations were signiﬁcantly higher in Group B than in
Group A. In contrast, the rates of hypertension, diabetes,
living donations, and ABO-incompatibility were signiﬁcantly
higher in Group A than in Group B. The rate of human
leukocyte antigen (HLA)-A, B, or DR mismatch did not
signiﬁcantly differ between groups. The patients with hep-
atitis C virus infection included asymptomatic carriers
(Group A, n ¼ 1), those with chronic hepatitis (Group A,
n ¼ 3; Group B, n ¼ 3), and those with liver cirrhosis
(Group A, n ¼ 3; Group B, n ¼ 2). None of these 12
patients received antivirus treatment.
During a mean follow-up of 10.3  7.3 years, 12 patients
died, 34 experienced loss of graft function, and 22 experi-
enced cardiovascular events. The causes of death were acute
myocardial infarction (Group A, n ¼ 2), hepatic failure
(Group A, n ¼ 2), pneumonia (Group A, n ¼ 1; Group B,n ¼ 1), subarachnoid hemorrhage (Group A, n ¼ 1), lung
cancer (Group A, n ¼ 1), accidental death (Group A,
n ¼ 1), cerebral infarction (Group B, n ¼ 1), and unknown
(Group A, n ¼ 2). The speciﬁc cardiovascular events
included acute myocardial infarction (Group A, n ¼ 6;
Group B, n ¼ 2), angina pectoris (Group A, n ¼ 4), heart
failure (Group A, n ¼ 4; Group B, n ¼ 3), cerebral hem-
orrhage with cerebral infarction (Group A, n ¼ 1), cerebral
infarction (Group A, n ¼ 1), and subarachnoid hemorrhage
(Group A, n ¼ 1). Fig 1 shows the Kaplan-Meier curves for
patient survival. The 5- and 10-year survival rates were
97.0% and 95.4%, respectively, in Group A, and 97.1% and
97.1%, respectively, in Group B. Fig 2 shows the Kaplan-
Meier curves for graft survival. The 5- and 10-year graft
survival rates were 95.4% and 84.8%, respectively, in
Group A, and 97.1% and 73.1%, respectively, in Group B.
There were no signiﬁcant differences between groups in
terms of patient survival and graft survival. Fig 3 shows the
Kaplan-Meier curves for cardiovascular events. The 5- and
10-year cardiovascular event-free survival rates were 95.9%
and 92.4%, respectively, in Group A and 88.6% and 76.8%,
respectively, in Group B. Cardiovascular event-free survival
was signiﬁcantly higher in Group A (P ¼ .038).
The results of the Cox regression analysis of cardiovas-
cular events are shown in Table 2. Patient age (hazard
ratio, 1.05; 95% conﬁdence interval, 1.01e1.09), history of
cardiovascular disease (hazard ratio, 8.98; 95% conﬁdence
interval, 2.77e29.17), and length of dialysis (hazard ratio,
1.006; 95% conﬁdence interval, 1.001e1.010) were signiﬁ-
cant predictors for cardiovascular events according to
univariate analysis. Cox stepwise multivariate analysis,
which included all variables with P < .05 in univariate
analysis, indicated that history of cardiovascular disease
(hazard ratio, 10.83; 95% conﬁdence interval, 3.25e36.08)
and length of dialysis (hazard ratio, 1.007; 95% conﬁdence
interval, 1.001e1.012) were signiﬁcant independent
predictors.
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Fig 3. Kaplan-Meier curves for cardiovascular events. The car-
diovascular event-free survival was signiﬁcantly higher in Group
A (P ¼ .038). The solid line represents Group A (dialysis <15
years), and the dotted line represents Group B (dialysis 15
years).
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In the present study, we compared patient backgrounds and
prognosis between 2 groups of patients undergoing kidney
transplantation: Group A with a length of dialysis of <15
years and Group B with a length of dialysis of 15 years. In
Japan, recipients of deceased donor kidney transplants are
chosen by the Japan Organ Transplant Network according
to their guidelines. Thus, the opportunity for receiving
donations from deceased donor kidney is equal among in-
stitutions in Japan. Therefore, we believe that our cohort of
patients who received deceased kidney donations repre-
sented the Japanese population of kidney failure patients
awaiting kidney transplantation.
The rate of diabetes was 12.4% in Group A and 0% in
Group B. In Japan, the rate of diabetes as the original
disease in recipients of donor kidneys is small. In 2009,Table 2. Cox Regression Analysi
Nonadjusted
HR (95% CI)
Age 1.05 (1.01e1.09)
Male 1.03 (0.43e2.43)
Deceased kidney donor 1.81 (0.70e4.67)
Smoking history 1.44 (0.62e3.32)
Previous CVD 8.98 (2.77e29.17)
BMI 1.09 (0.94e1.26)
Diabetes 0.93 (0.22e4.00)
LVH 2.42 (0.99e5.94)
Systolic BP 1.01 (0.99e1.03)
Diastolic BP 1.02 (0.99e1.05)
Dialysis length 1.006 (1.001e1.010)
Note: The multivariate model included all the variables with a P value of <.05 on u
Abbreviations: HR, hazard ratio; CI, conﬁdence interval.1 year before the revised organ transplantation law was
introduced, there were 10 diabetic patients of a total 171
patients who underwent deceased donor kidney trans-
plantation (5.8%) and 159 diabetic patients of a total 1041
patients who underwent living-donor kidney trans-
plantation (15.3%) [4]. Thus, the 12.4% of diabetic pa-
tients in our cohort are similar to the proportion of all
Japanese recipients. The prognosis of diabetic dialysis
patients is poor. Ningyan et al reported that patients with
diabetes experienced cardiovascular events that resulted
in their removal from the transplantation wait list with a
median time of 8.16 years [5]. Cardiovascular disease is
the most common cause of death in diabetic patients,
accounting for more than one half of cases [6]. According
to these disease backgrounds, the opportunity to become
a recipient candidate was small in diabetic patients with a
long length of dialysis.
The mean body mass index (BMI) of our cohort was
20.1 kg/m2. There was no difference between Group A and
Group B. According to previous research, the mean BMI of
dialysis patients was 21.5 kg/m2 in 2012 and 20.7 kg/m2 in
2001 [3]. Our cohort included patients from October 1990
to March 2014. The low mean BMI might have been
inﬂuenced by patients who underwent transplantation in the
1990s and 2000s. In fact, the mean BMI from 2010 to 2014
in our cohort was 20.9  3.9 kg/m2.
Four patients in Group B received kidneys from living
donors; the reason for their long duration on dialysis before
kidney transplantation, from living donors, was their lack of
knowledge regarding kidney transplantation as a treatment
for end-stage renal disease. In a survey among patients with
end-stage renal disease on the adequacy of information
provided on renal replacement therapies, an “excellent and
good” status was reported in 80.8% for information pro-
vided on hemodialysis, 49.8% for information provided on
peritoneal dialysis, and 32.5% for information provided on
kidney transplantation [7]. The number of new dialysis pa-
tients was 38,055, and kidney transplantation was performed
in only 1610 patients in 2012 [2]. It is the duty of thes for a Cardiovascular Event
Adjusted
P HR (95% CI) P
.007 1.03 (0.99e1.07) .21
.95
.22
.40
<.0001 10.83 (3.25e36.08) <.0001
.26
.91
.053
.44
.20
.028 1.007 (1.001e1.012) .012
nivariate analysis.
30 TADA, HASEGAWA, SASAKI ET ALphysician to explain the 3 types of renal replacement ther-
apies to patients with end-stage renal disease.
It is unclear whether long-term dialysis is related to graft
or patient survival. Kimura et al [8] and Kohei et al [9]
demonstrated that the outcomes of kidney transplantation
in long-term dialysis patients were similar to those in short-
term dialysis patients. In contrast, Cosio et al [10] concluded
that an increased time on dialysis prior to kidney trans-
plantation was associated with decreased survival in trans-
plant recipients. In our cohort, there were no signiﬁcant
differences in patient or graft survival between groups.
However, the cardiovascular event-free survival rate was
superior in Group A. Cox stepwise multivariate analysis,
which included all variables with a P value of <.05 on uni-
variate analysis, indicated that length of dialysis was a sig-
niﬁcant predictor of cardiovascular events. Meier-Kriesche
et al [11] compared the rate of cardiac death in kidney
transplantation patients according to length since trans-
plantation with that of patients on the waiting list for donor
kidneys according to length on the waiting list. The car-
diovascular disease rates peaked during the ﬁrst 3 months
following transplantation and decreased subsequently ac-
cording to time since transplantation. In contrast, the car-
diovascular disease rates among patients on the
transplantation waiting list increased sharply and progres-
sively according to the length of time on the waiting list.
Their data suggest that the development or progression of
atherosclerosis and cardiovascular disease could be
ameliorated by the restoration of renal function with a
transplant. In Japan, the 5 major causes of death in dialysis
patients are heart failure (27.2%), infection (20.4%), ma-
lignancy (9.1%), cerebrovascular disease (7.5%), and acute
myocardial infarction (4.5%) [3]. Total cardiovascular dis-
ease accounts for 39.2% of these causes of death. On the
other hand, the 5 major causes of death among transplant
recipients were infection (20.2%), heart disease (11.8%),
malignancy (15.1%), cerebrovascular disease (10.0 %), and
intestinal disease (8.6%). Total cardiovascular disease ac-
counts for 21.8% of these causes of death [4]. The rate of
cardiovascular disease was higher in dialysis patients than in
transplant recipients. These epidemiological results also
support the higher risk of cardiovascular disease in dialysis
patients.
Testing for coronary artery disease includes noninvasive
measures, such as myocardial perfusion studies, dobutamine
stress echocardiography, or assessment of biomarker levels.
The American Society of Transplantation recommends that
high-risk patients undergo a cardiac stress test [12]. The risk
factors for determining patients at high-risk include a prior
history of coronary artery disease, age of >45 years for men
or >55 years for women, coronary artery disease in a ﬁrst-
degree relative, current cigarette smoking status, diabetes,
hypertension, fasting total cholesterol >200 mg/dL, high-
density lipoprotein cholesterol <35 mg/dL, and left ven-
tricular hypertrophy [12]. In patients with a long length of
dialysis or in those who have at least 1 risk factor, nonin-
vasive tests are required.This study has certain limitations. First, it was a single-
center study. Second, precise lipid data were lacking until
1997, and, therefore, we could not evaluate the relationships
between cardiovascular events and lipid levels.
In conclusion, there were no signiﬁcant differences in
patient survival or graft survival according to dialysis vin-
tage. Patients with a length of dialysis of 15 years prior to
transplantation had an inferior cardiovascular event-free
survival rate compared with patients with a short length of
dialysis, and their rate of hepatitis C virus infection was also
high. It is important for physicians to provide appropriate
information concerning renal replacement therapy,
including kidney transplantation, to patients with end-stage
renal disease. For patients with a long length of dialysis,
evaluation of cardiovascular risk is necessary. Further
studies are required to fully evaluate the risks associated
with transplantation in patients with a long length of
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